NEW RESIDENT OF SEZ TECHNOPOLIS MOSCOW WILL PRODUCE DRUGS FOR RARE DISEASES
The company Generium Next received the status of a resident of SEZ Technopolis Moscow, where it will produce drugs, including for the treatment of rare, so-called orphan diseases. This was announced by Alexander Prokhorov, Head of the Department for Investment and Industrial policy of Moscow
Among the drugs that the new resident will produce are drugs for the treatment of bronchial asthma, cardiovascular, rare and hereditary diseases. These are, for example, Gaucher disease and cystic fibrosis. After launching its own workshops, the company will produce substances and finished dosage forms, primary and secondary packaging for medicines.
"The production capacity of the enterprise will be designed to produce more than 150 thousand units of products per year, which is also facilitated by convenient logistics and cooperation within the cluster of medical technologies of Technopolis Moscow SEZ, which will include a new resident," said Gennady Degtev, CEO of SEZ Technopolis Moscow.
Generium Next specializes in providing the healthcare system of the Russian Federation with modern genetically engineered medicines of domestic production for the treatment of severe and socially significant pulmonological, cardiovascular and orphan diseases. All drugs within the framework of the project are included by the Russian Ministry of Health in the list of vital and essential drugs.
“The construction of a high-tech pharmaceutical production is in line with Generium-Next's development plans to increase production and requires the necessary conditions and support from the manufacturer. All these opportunities are best reflected in the concept of the special economic zone Alabushevo SEZ Technopolis Moscow", - said General Director of LLC Generium Next Alexander Andryushechkin.